ICON Plc (ICLR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the analyst to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:
Business description - A detailed description of the company’s operations and business divisions.
Corporate strategy - Analyst’s summarization of the company’s business strategy.
SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
Company history - Progression of key events associated with the company.
Major products and services - A list of major products, services and brands of the company.
Key competitors - A list of key competitors to the company.
Key employees - A list of the key executives of the company.
Executive biographies - A brief summary of the executives’ employment history.
Key operational heads - A list of personnel heading key departments/functions.
Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights
ICON Plc (ICON) is a contract research organization (CRO) that provides outsourced development services to the biotechnology, pharmaceutical and medical device industries worldwide. The company provides specialized services that span the entire lifecycle of product development. ICON’s service portfolio includes clinical solutions, blended solutions, cardiac safety solutions, clinical and scientific operations, decentralised clinical trials, early clinical laboratories, medical imaging, site & patient solutions, strategic solutions. The company offers research services in areas of cancer, genomics, central nervous system, cardiovascular, endocrine and metabolic disorders, gastrointestinal, medical device, non-alcoholic steatohepatitis (NASH), ophthalmology, rare and orphan diseases, transplant and immunology, vaccines, and women’s health, among others. ICON is headquartered in Dublin, Ireland.
ICON Plc Key Recent Developments
Jun 23, 2026: ICON Reports First Quarter 2026 Results
Jun 22, 2026: ICON Selects Microsoft as Preferred Technology Partner for AI-Enabled Clinical Development
Jun 17, 2026: ICON Schedules Q1 2026 Earnings Call
May 27, 2026: ICON Reports Fourth Quarter and Full Year 2025 Results and Audit Committee Investigation Outcome
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
Table of Contents
Section 1 - About the Company
PT Kimia Farma Tbk - Key Facts
PT Kimia Farma Tbk - Key Employees
PT Kimia Farma Tbk - Major Products and Services
PT Kimia Farma Tbk - History
PT Kimia Farma Tbk - Company Statement
PT Kimia Farma Tbk - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 - Company Analysis
Company Overview
PT Kimia Farma Tbk - Business Description
Business Segment: Distribution
Overview
Performance
Business Segment: Manufacture
Overview
Performance
Key Stats
Business Segment: Others
Overview
Performance
Business Segment: Retail
Overview
Performance
R&D Overview
PT Kimia Farma Tbk - Corporate Strategy
PT Kimia Farma Tbk - SWOT Analysis
SWOT Analysis - Overview
PT Kimia Farma Tbk - Strengths
PT Kimia Farma Tbk - Weaknesses
PT Kimia Farma Tbk - Opportunities
PT Kimia Farma Tbk - Threats
PT Kimia Farma Tbk - Key Competitors
Section 3 - Company Financial Ratios
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
PT Kimia Farma Tbk, Pharmaceuticals & Healthcare, Deals By Year, 2020 to YTD 2026
PT Kimia Farma Tbk, Pharmaceuticals & Healthcare, Deals By Type, 2020 to YTD 2026
PT Kimia Farma Tbk, Recent Deals Summary
Section 5 - Company’s Recent Developments
Apr 06, 2026: PT Kimia Farma Launches Stemxera and Expands Biotechnology Collaboration
Dec 30, 2025: EGMS Approves Transfer of PT Kimia Farma Tbk Assets
Oct 16, 2025: PT Kimia Farma Tbk is Collaborating on Export Distribution with Soidal Medical Supplies Ltd Papua New Guinea
Oct 13, 2025: KIMIA FARMA, in Collaboration with RSCM, Expands Stem Cell Therapy Services
Mar 03, 2025: Kimia Farma is Partnering with Samsung Pharm For Providing Production Facilities
Section 6 - Appendix
Methodology
Ratio Definitions
About the Analyst
Contact the Publisher
Disclaimer
List of Tables
PT Kimia Farma Tbk, Key Facts
PT Kimia Farma Tbk, Key Employees
PT Kimia Farma Tbk, Major Products and Services
PT Kimia Farma Tbk, History
PT Kimia Farma Tbk, Other Locations
PT Kimia Farma Tbk, Subsidiaries
PT Kimia Farma Tbk, Key Competitors
PT Kimia Farma Tbk, Ratios based on current share price
PT Kimia Farma Tbk, Annual Ratios
PT Kimia Farma Tbk, Interim Ratios
PT Kimia Farma Tbk, Pharmaceuticals & Healthcare, Deals By Year, 2020 to YTD 2026
PT Kimia Farma Tbk, Pharmaceuticals & Healthcare, Deals By Type, 2020 to YTD 2026
PT Kimia Farma Tbk, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios
List of Figures
PT Kimia Farma Tbk, Performance Chart (2021 - 2025)
PT Kimia Farma Tbk, Ratio Charts
PT Kimia Farma Tbk, Pharmaceuticals & Healthcare, Deals By Year, 2020 to YTD 2026
PT Kimia Farma Tbk, Pharmaceuticals & Healthcare, Deals by Type, 2020 to YTD 2026
This product is a company SWOT Analysis. Each license type allows a set number of users to access the report. Please select an option from the list below. This product is a company SWOT Analysis. This is a single user license, allowing one user access to the product. The product is a PDF. This product is a company SWOT Analysis. This is a site license, allowing all users within a given geographical location of your organization access to the product. The product is a PDF.
The sample excerpt is provided to help you make an informed purchasing decision. It is not intended to serve as free content or replace a full report. To ensure the sample aligns with your specific needs, our team will contact you to better understand your requirements.
An error occurred while sending the message. Should this issue persist, email us at help@researchandmarkets.net
This report can be tailored to focus on a specific country, region, continent, or provide global coverage. Please indicate your regions of interest and share any additional questions you may have. Our team strives to respond to all inquiries within the same business day.
An error occurred while sending the message. Should this issue persist, email us at help@researchandmarkets.net